{"id":2475,"date":"2017-04-25T09:42:11","date_gmt":"2017-04-25T09:42:11","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=2475"},"modified":"2022-06-21T15:24:48","modified_gmt":"2022-06-21T15:24:48","slug":"problems-with-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/problems-with-immunotherapy\/","title":{"rendered":"Problems with Immunotherapy"},"content":{"rendered":"

Pairs of proteins that act as T-cell co-signaling receptors are called immune checkpoints. These cell surface receptors can send positive or negative signals to T cells, instigating a response from the immune system to either stimulate the immune system against cells carrying the antigen or ignore the bound target. In the case of Programmed cell Death-1 (PD-1)<\/a>, its ligand, Programmed cell Death-Ligand-1 (PD-L1)<\/a>, causes a tolerance response in the T cell. This pathway is suggested to be important for self-tolerance, allowing the immune system to differentiate pathogens from the body\u2019s own cells. In some cancers, PD-L1 is overexpressed, which causes serious problems due to the muting effect it has on the immune system in response to the threat of cancer, allowing it to grow without detection. There are ways to help the immune system recognize cancer<\/a> and improve response. Immunotherapy is one way to train the immune system to more efficiently attack cancer cells by supplying
\nadditional components, such as artificial immune system proteins.<\/p>\n

The PD-L1 Blockade<\/strong><\/p>\n

One effective immunotherapy technique takes advantage of this immune checkpoint is PD-L1 blockade<\/a>, where the tolerance signal is removed and the immune system no longer receives a negative signal from PD-L1. This allows T-cells and other immunocytes to identify the cancers and produce a response. This treatment is called immune system checkpoint inhibition. Some early cases which exhibited a lack of patient response cast doubt on the efficacy of immunotherapy as a treatment for cancers.<\/p>\n

 <\/p>\n

Alternate Pathways<\/strong><\/p>\n

There are some specific subsets of tumors in patients which do not respond to treatment with Ipilimumab, an Anti-CTLA-4<\/a> therapy. Genomic studies elucidated one possible cause<\/a>; the loss of signaling pathway fidelity caused by mutations in the genes of receptors or ligands on non-responder tumors makes treatment of cancers like melanoma using immunotherapy the incorrect choice for treatment. Targeting PD-L1, which is upstream of IFN-\u03b3 in the activation of the immune response, will not aid activation if the problem is further downstream in the pathway. Patient genotyping is critical in some cases to determine the most effective treatment options on a case-by-case basis.<\/p>\n


\nWhat Can Be Done?<\/strong><\/p>\n

There is a rising need for bedside genotyping for prognostic determination of treatment options. The molecular and genetic properties of a cancer have an impact on the immune system\u2019s ability to fight it. Scientists and medical specialists agree that there are no universal treatments for inducing an effective immune cytolytic response against cancers. Understanding the genetics of a cancer is critical<\/a> in determining the efficacy of immune checkpoint mAbs and helps pave the way to personalized healthcare.<\/p>\n

 <\/p>\n

Originally posted by ProSci<\/a><\/p>\n

 <\/p>\n

Find out how ProSci can help your Antibody needs today!<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Pairs of proteins that act as T-cell co-signaling receptors are called immune checkpoints. These cell surface receptors can send positive or negative signals to T cells, instigating a response from the immune system to either stimulate the immune system against<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[7,50,158,157,260,261,77],"class_list":["post-2475","post","type-post","status-publish","format-standard","hentry","category-antibodies","tag-cancer","tag-immunology","tag-immunotherapy","tag-pd-1","tag-pd-l1","tag-personalized-medicine","tag-prosci"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=2475"}],"version-history":[{"count":5,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2475\/revisions"}],"predecessor-version":[{"id":6742,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2475\/revisions\/6742"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=2475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=2475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=2475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}